{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:05:23Z","timestamp":1776175523446,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272881"],"award-info":[{"award-number":["82272881"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109380","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T23:01:43Z","timestamp":1774220503000},"page":"109380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study"],"prefix":"10.1016","volume":"215","author":[{"given":"Yan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xirui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1168-8803","authenticated-orcid":false,"given":"Weidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6607-9068","authenticated-orcid":false,"given":"Jianhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109380_b0005","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Published online April 4, 2024. doi:10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"10.1016\/j.lungcan.2026.109380_b0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology- (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer (2025 Version 5). Available from http:\/\/www.nccn.org."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109380_b0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109380_b0020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2026.109380_b0025","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non\u2013small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"JCO"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109380_b0030","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109380_b0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109380_b0040","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10459","key":"10.1016\/j.lungcan.2026.109380_b0045","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109380_b0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non\u2013small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109380_b0055","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109380_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"issue":"28","key":"10.1016\/j.lungcan.2026.109380_b0070","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109380_b0075","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1097\/CM9.0000000000002544","article-title":"Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109380_b0085","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10147-023-02385-z","article-title":"Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis","volume":"28","author":"Okamoto","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109380_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109380_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101512","article-title":"Immunomodulatory effects of G-CSF in cancer: Therapeutic implications","volume":"54","author":"Mouchemore","year":"2021","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/febs.14343","article-title":"The roles of CSFs on the functional polarization of tumor-associated macrophages","volume":"285","author":"Jeannin","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.lungcan.2026.109380_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111705","article-title":"G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastases","volume":"130","author":"Luo","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0110","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1038\/s41467-024-51807-7","article-title":"Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: the multicenter SWORD phase 2 trial","volume":"15","author":"Ni","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109380_b0115","doi-asserted-by":"crossref","unstructured":"Xie M, Liu B, Chen Z, Cao T, Zhang X. Transcriptomic Signatures in TP53 Positive and Negative Tumor Samples in NSCLC. Curr Gene Ther. Published online August 8, 2025. doi:10.2174\/0115665232357300250805021330.","DOI":"10.2174\/0115665232357300250805021330"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/0115665232340926241105064739","article-title":"The role of immunotherapy in lung cancer treatment: current strategies, future directions, and insights into metastasis and immune microenvironment","volume":"25","author":"Li","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.lungcan.2026.109380_b0125","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109380_b0130","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The international association for the study of lung cancer lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer","volume":"19","author":"Rami-Porta","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109380_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952066","article-title":"PD-1 Inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase II study","volume":"13","author":"Kong","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0140","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ijrobp.2020.08.023","article-title":"Radiation therapy and the in situ vaccination approach","volume":"108","author":"Golden","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109380_b0145","article-title":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator","volume":"12","author":"Lazarus","year":"2021","journal-title":"A Drug before Its Time? Front Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109380_b0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3RU0316-144R","article-title":"Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage","volume":"100","author":"Ushach","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/0008-5472.CAN-12-0806","article-title":"Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors","volume":"73","author":"Urdinguio","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-024-01641-7","article-title":"Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells","volume":"17","author":"Pezzella","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109380_b0165","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers12102868","article-title":"G-CSF and G-CSFR induce a pro-tumorigenic macrophage phenotype to promote colon and pancreas tumor growth","volume":"12","author":"Karagiannidis","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109380_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155479","article-title":"G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation","volume":"142","author":"Karagiannidis","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109380_b0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-024-02004-z","article-title":"Neutrophils in Cancer immunotherapy: friends or foes?","volume":"23","author":"Huang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109380_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.02.005","article-title":"Neutrophil profiling illuminates anti-tumor antigen-presenting potency","volume":"187","author":"Wu","year":"2024","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109380_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111171","article-title":"During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes","volume":"40","author":"Pylaeva","year":"2022","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0190","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.celrep.2014.12.039","article-title":"Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer","volume":"10","author":"Sagiv","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109380_b0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/0115665232292768240503050508","article-title":"Lipid-based nanocarriers for targeted gene delivery in lung cancer therapy: exploring a novel therapeutic paradigm","volume":"25","author":"Beigi","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.lungcan.2026.109380_b0200","article-title":"The mediating role of miR-451\/ETV4\/MMP13 signaling axis on epithelialmesenchymal transition in promoting non-small cell lung cancer progression","volume":"17","author":"Qian","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109380_b0205","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","article-title":"Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy","volume":"119","author":"van de Laar","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0210","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0215","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cam4.239","article-title":"A role for G-CSF and GM-CSF in nonmyeloid cancers","volume":"3","author":"Aliper","year":"2014","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109380_b0220","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109380_b0225","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41391-021-00321-8","article-title":"Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial","volume":"24","author":"Barqawi","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109380_b0230","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1021\/acs.molpharmaceut.2c00897","article-title":"Design of a tumor binding GMCSF as intratumoral immunotherapy of solid tumors","volume":"20","author":"Chakravarti","year":"2023","journal-title":"Mol. Pharm."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:23:56Z","timestamp":1776173036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":46,"alternative-id":["S0169500226004411"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109380","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109380"}}